KR950702580A - 니메술라이드 염 시클로덱스트린 봉입 복합체(new nimesulide salt cyclodextrine inclusion complexes) - Google Patents
니메술라이드 염 시클로덱스트린 봉입 복합체(new nimesulide salt cyclodextrine inclusion complexes) Download PDFInfo
- Publication number
- KR950702580A KR950702580A KR1019950700275A KR19950700275A KR950702580A KR 950702580 A KR950702580 A KR 950702580A KR 1019950700275 A KR1019950700275 A KR 1019950700275A KR 19950700275 A KR19950700275 A KR 19950700275A KR 950702580 A KR950702580 A KR 950702580A
- Authority
- KR
- South Korea
- Prior art keywords
- cyclodextrin
- nimesulide
- alkali
- alkaline earth
- inclusion complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract 20
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract 19
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical class CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 title claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000003513 alkali Substances 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 8
- 229960000965 nimesulide Drugs 0.000 claims abstract 7
- 238000005538 encapsulation Methods 0.000 claims abstract 4
- 150000002500 ions Chemical class 0.000 claims abstract 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 4
- 229960004853 betadex Drugs 0.000 claims 4
- CKEPVOKIMGDTQO-UHFFFAOYSA-N n-(4-nitro-2-phenoxyphenyl)methanesulfonamide;sodium Chemical compound [Na].CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 CKEPVOKIMGDTQO-UHFFFAOYSA-N 0.000 claims 4
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001760 anti-analgesic effect Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 229940097362 cyclodextrins Drugs 0.000 claims 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 claims 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 150000004679 hydroxides Chemical class 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 238000007738 vacuum evaporation Methods 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
본 발명은 하기 일반식(Ⅰ)의 니메술라이드 알칼리 및 알칼리 토류 염과 시클로덱스트린 및 시클로덱스트린 유도체와의 봉입 복합체, 이것을 포함하는 조성물, 니메술라이드 염의 복합체화에 의한 상기 봉입 복합체의 제조 방법 및 약제로서 이것을 사용하는 방법에 관한 것이다.
상기 식에서, A는 알칼리 및 알칼리 토류 이온을 나타낸다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명의 화합물의구조식이고,
제2도는 SLAP술라이드의 염과 상기 염/β CD 복합체의 pH에 따른 함량을 도시한 그래프이고,
제3A도 및 B도는 각각 본 발명의 화합물의 온도에 따른 열흐름을 도시한 그래프이다.
Claims (11)
- 하기 일반식(Ⅰ)의 니메술라이드 알칼리 및 알칼리 토류 염과 시클로덱스트린 및 시클로덱스트린 유도체와의 봉입 봉합체 :상기 식에서, A는 알칼리 및 알칼리 토류 이온을 나타낸다.
- 염의 시클로덱스트린에 대한 몰 비율이 1 : 1 또는 1 : 2인 니메술라이드 나트륨, 칼륨, 마그네슘 또는 칼슘 염과 β-시클로덱스트린 또는 감마 시클로덱스트린과의 봉입 복합체.
- 제1항에 있어서, 시클로덱스트린 및 시클로덱스트린 유도체가 α, β 및 감마시클로덱흐트린, 및/또는 시클로덱스트린의 알킬 또는 히록시알킬 유도체, 바람직하게는 메틸 β-시클로덱스트린 또는 히드록시프로필-β-시클로덱스트린인 것을 특징으로 하는 봉입 복합체.
- 제1항에 있어서, 니메술라이드 알칼리가 니메술라이드 나트륨 염인 것을 특징으로 하는 봉입 복합체.
- 니메술라이드 알칼리 및 알칼리 토류 염을 물의 존재하에 시클로덱스트린 또는 시클로덱스트린 유도체와 pH 7 내지 pH 9.5, 바람직하게는 pH 7.5 내지 8.5에서 반응시키는 것을 특징으로 하는, 니메술라이드 알칼리 및 알칼리 토류 염과 시클로덱스트리 또는 시클로덱스트린 유도체와의 봉입 복합체의 제조방법.
- 제5하에 있어서, 물중의 SLAP술라이드의 현탁액을 알칼리 및 알칼리 토류 수산화물, 알칼리 및 알칼리 토류 탄산염, -탄산 수소-, 인산염, 바람직하게는 수산화 나트륨, 인산 이나트륨 및/또는 탄산 수소 나트룸 또는 다른 완충제를 사용하여 7 내지 9.5, 바람직하게는 7.5 내지 8.5의 pH값으로 조정함으로써 반응 혼합물중에서 제자리 형성된 니메술라이드 알칼리 및 알칼리 토류 염을 사용하는 것을 특징으로 하는 방법.
- 제5항 또는 6항에 있어서, 복합체 형성후에 동결-건조, 분무-건조, 저온 진공 증발, 진공 건조 또는 다른 공지의 방법에 의하여 물을 제거하는 것을 특징으로 하는 방법.
- 활성 성분으로서 니메술라이드 알칼리 및 알칼리 토류 염과 시클로덱스트린 또는 시클로덱스트린 유도체와의 봉입 복합체를 함유하는 것을 특징으로 하는, 니메술라이드 및 시클로덱스트린 또는 시클로덱스트린 유도체를 포함하는 고도로 가용성의 생리적으로 허용되는 봉입 복합체를 함유하는 약제학적 조성물.
- 제8항에 있어서, 활성 성분으로서 니메술라이드 나트륨 염과 β-시클로덱스트린의, 가능하다면 다른 약제학적으로 허용되는 성분들과의 봉입 복합체를 함유하는 것을 특징으로 하는 약제학적 조성물.
- 니메술라이드 알칼리 및 알칼리 토류 염과 형성된 시클로덱스트린 또는 시클로덱스트린 유도체의 봉입 복합체의 유효량을 환자에게 투여하는 것을 특징으로 하는, 항염증 및/또는 진통 치료가 요구되는 환자의 치료 방법.
- 니메술라이드 나트륨 염과 형성된 β-시클로덱스트린의 봉입 복합체의 유료량을 환자에게 투여하는 것을 특징으로 하는, 항염증 및/또는 진통 치료가 요구되는 환자의 치료 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9301518A HU210922B (en) | 1993-05-24 | 1993-05-24 | Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them |
| HUP93-01518 | 1993-05-24 | ||
| PCT/HU1994/000014 WO1994028031A1 (en) | 1993-05-24 | 1994-05-18 | New nimesulide salt cyclodextrin inclusion complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950702580A true KR950702580A (ko) | 1995-07-29 |
Family
ID=10983630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950700275A Withdrawn KR950702580A (ko) | 1993-05-24 | 1994-05-18 | 니메술라이드 염 시클로덱스트린 봉입 복합체(new nimesulide salt cyclodextrine inclusion complexes) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5744165A (ko) |
| EP (1) | EP0656015B1 (ko) |
| JP (1) | JPH07509498A (ko) |
| KR (1) | KR950702580A (ko) |
| AT (1) | ATE170194T1 (ko) |
| AU (1) | AU675146B2 (ko) |
| CA (1) | CA2140887C (ko) |
| CZ (1) | CZ285962B6 (ko) |
| DE (1) | DE69412760T2 (ko) |
| DK (1) | DK0656015T3 (ko) |
| ES (1) | ES2124893T3 (ko) |
| FI (1) | FI950294A7 (ko) |
| HU (1) | HU210922B (ko) |
| NO (1) | NO307570B1 (ko) |
| RU (1) | RU2129564C1 (ko) |
| SI (1) | SI0656015T1 (ko) |
| WO (1) | WO1994028031A1 (ko) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960700361A (ko) * | 1993-02-19 | 1996-01-20 | 우에하라 아키라 | 5-아미노아세틸아미노술폰아닐리드 화합물 |
| HUP9601442A3 (en) * | 1995-07-25 | 1999-03-29 | Panacea Biotec Ltd | Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IN186315B (ko) * | 1996-12-12 | 2001-08-04 | Panacea Biotec Ltd | |
| ES2129010B1 (es) * | 1997-01-02 | 2000-01-16 | Gold Oscar | Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion. |
| IT1291895B1 (it) | 1997-04-24 | 1999-01-21 | Errekappa Euroterapici S P A | Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo |
| IT1298221B1 (it) * | 1998-02-10 | 1999-12-20 | Helsinn Healthcare Sa | Sali micronizzati di nimesulide |
| RU2238087C2 (ru) * | 1999-09-28 | 2004-10-20 | Панацея Биотек Лимитед | Композиции контролируемого высвобождения, содержащие нимесулид |
| IT1318588B1 (it) * | 2000-06-20 | 2003-08-27 | Helsinn Healthcare Sa | Uso della nimesulide nel trattamento di patologie dermatologiche. |
| EP1172101A1 (en) * | 2000-06-20 | 2002-01-16 | Helsinn Healthcare S.A. | The use of nimesulide for the treatment of psoriasis and psoriatic arthritis |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| ES2377318T3 (es) | 2002-09-06 | 2012-03-26 | Cerulean Pharma Inc. | Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos |
| CA2501132A1 (en) | 2002-10-09 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based materials, compositions and uses related thereto |
| CN1511828A (zh) * | 2002-12-31 | 2004-07-14 | �й������ž�����ҽѧ��ѧԺ����ҽ | 磺酰苯胺类衍生物及其医药用途 |
| DE102004060914A1 (de) * | 2004-12-17 | 2006-07-06 | Bioghurt Biogarde Gmbh & Co. Kg | Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| RU2363473C1 (ru) * | 2008-02-18 | 2009-08-10 | Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава | Способ антифлогистической активации в эксперименте |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CN109608370A (zh) * | 2019-01-22 | 2019-04-12 | 山西康斯亚森生物科技有限公司 | 尼美舒利衍生物和制备方法及用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5920230A (ja) * | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | ピルプロフエン含有薬剤 |
| SU1513880A1 (ru) * | 1987-12-21 | 1991-05-07 | Inst Khim Bashkirskogo Nauchno | Tpиc(диизoпpoпokcи)aлюmиhиebaя coль глициppизиhoboй kиcлotы, пpoяbляющaя пpotиbobocпaлиteльhую и пpotиboязbehhую aktиbhoctь |
| GB8813682D0 (en) * | 1988-06-09 | 1988-07-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
| IT1248475B (it) * | 1990-05-22 | 1995-01-19 | Angeli Inst Spa | Composti di inclusione di nimesulide con ciclodestrine |
| AU7606696A (en) * | 1995-11-07 | 1997-05-29 | Seiko Communications Systems, Inc. | Selective advertisement presentation |
-
1993
- 1993-05-24 HU HU9301518A patent/HU210922B/hu not_active IP Right Cessation
-
1994
- 1994-05-18 CA CA002140887A patent/CA2140887C/en not_active Expired - Fee Related
- 1994-05-18 KR KR1019950700275A patent/KR950702580A/ko not_active Withdrawn
- 1994-05-18 WO PCT/HU1994/000014 patent/WO1994028031A1/en not_active Ceased
- 1994-05-18 JP JP7500436A patent/JPH07509498A/ja active Pending
- 1994-05-18 EP EP94919796A patent/EP0656015B1/en not_active Expired - Lifetime
- 1994-05-18 SI SI9430204T patent/SI0656015T1/xx unknown
- 1994-05-18 AU AU70813/94A patent/AU675146B2/en not_active Ceased
- 1994-05-18 DE DE69412760T patent/DE69412760T2/de not_active Expired - Fee Related
- 1994-05-18 AT AT94919796T patent/ATE170194T1/de not_active IP Right Cessation
- 1994-05-18 US US08/374,765 patent/US5744165A/en not_active Expired - Lifetime
- 1994-05-18 CZ CZ95163A patent/CZ285962B6/cs not_active IP Right Cessation
- 1994-05-18 ES ES94919796T patent/ES2124893T3/es not_active Expired - Lifetime
- 1994-05-18 DK DK94919796T patent/DK0656015T3/da active
- 1994-05-18 RU RU95105977A patent/RU2129564C1/ru active
-
1995
- 1995-01-23 NO NO950243A patent/NO307570B1/no not_active IP Right Cessation
- 1995-01-24 FI FI950294A patent/FI950294A7/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE170194T1 (de) | 1998-09-15 |
| NO950243D0 (no) | 1995-01-23 |
| DE69412760D1 (de) | 1998-10-01 |
| JPH07509498A (ja) | 1995-10-19 |
| HU210922B (en) | 1995-09-28 |
| EP0656015B1 (en) | 1998-08-26 |
| CZ285962B6 (cs) | 1999-12-15 |
| FI950294A0 (fi) | 1995-01-24 |
| WO1994028031A1 (en) | 1994-12-08 |
| FI950294A7 (fi) | 1995-01-24 |
| EP0656015A1 (en) | 1995-06-07 |
| ES2124893T3 (es) | 1999-02-16 |
| CZ16395A3 (en) | 1995-10-18 |
| AU7081394A (en) | 1994-12-20 |
| NO307570B1 (no) | 2000-04-25 |
| RU95105977A (ru) | 1997-02-10 |
| CA2140887A1 (en) | 1994-12-08 |
| NO950243L (no) | 1995-03-13 |
| HUT68239A (en) | 1995-06-28 |
| US5744165A (en) | 1998-04-28 |
| SI0656015T1 (en) | 1999-02-28 |
| DK0656015T3 (da) | 1999-05-25 |
| HU9301518D0 (en) | 1993-09-28 |
| RU2129564C1 (ru) | 1999-04-27 |
| DE69412760T2 (de) | 1999-05-20 |
| AU675146B2 (en) | 1997-01-23 |
| CA2140887C (en) | 2000-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950702580A (ko) | 니메술라이드 염 시클로덱스트린 봉입 복합체(new nimesulide salt cyclodextrine inclusion complexes) | |
| US4289754A (en) | Zinc derivatives and their use in mouthwash compositions | |
| SE7614258L (sv) | Forfarande for framstellning av kinazoloderivat | |
| NZ198144A (en) | Ammonium or alkali metal zinc citrate and dentifrice compositions thereof | |
| KR890011837A (ko) | 디데하이드로 비타민 d₃유도체 | |
| KR890015738A (ko) | 이포스폰산 유도체를 기제로 하는, 경구 투역용 약학적 조성물 | |
| KR890011823A (ko) | 벤조일 페닐아세트산 유도체 약제 조성물 | |
| KR920005978A (ko) | 안정화된 고형화학 조성물 | |
| KR910019612A (ko) | 옥살릴아미노산 유도체, 이의 제조방법 및 프롤린 하이드록실라제 억제용 약제로서의 이의 용도 | |
| HUP9701690A2 (hu) | Gombaellenes hatású tetrahidrofuránszármazékok és az ezeket tartalmazó gyógyszerkészítmények | |
| NO155966C (no) | Nye morfolinoforbindelser, preparat inneholdende disse og anvendelseav disse for aa hemme dannelsen av eller fjerne tann-plaque. | |
| IE41323L (en) | Pyrrolidon-5, 5-diphosphonic acids. | |
| KR880001295A (ko) | 약학조성물 | |
| KR970702291A (ko) | 에퀼린의 산 이성질화체로부터 제조된 에퀼린 이중결합 이성질체(Anequilin double bond isomer from the acid isomerization of equilin) | |
| KR900011754A (ko) | (디-3급-부틸히드록시페닐)티오 유도체 | |
| JP2540895B2 (ja) | 口腔用組成物 | |
| KR940002301A (ko) | 5,10-메틸렌테트라히드로폴산-시클로덱스트린 포접 화합물 | |
| RU95121629A (ru) | Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы | |
| NO941036L (no) | Sparfloxacinsalter og opplösninger inneholdende saltene | |
| JP2973511B2 (ja) | 口腔用組成物 | |
| JPS5931789A (ja) | １−ヒドロキシ−３−アミノプロパン−１，１−ジホスホン酸のゲル様カルシウム塩 | |
| JPH02292210A (ja) | 口腔用組成物 | |
| JP2814549B2 (ja) | 口腔用組成物 | |
| HU184890B (en) | Process for preparing an antimicrobial composition with increa sed staaility | |
| KR900014397A (ko) | 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19950124 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |